Literature DB >> 18571626

RASD2, MYH9, and CACNG2 genes at chromosome 22q12 associated with the subgroup of schizophrenia with non-deficit in sustained attention and executive function.

Yu-Li Liu1, Cathy Shen-Jang Fann, Chih-Min Liu, Wei J Chen, Jer-Yuarn Wu, Shuen-Iu Hung, Chun-Houh Chen, Yuh-Shan Jou, Shi-Kai Liu, Tzung-Jeng Hwang, Ming H Hsieh, Chien Ching Chang, Wei-Chih Yang, Jin-Jia Lin, Frank Huang-Chih Chou, Stephen V Faraone, Ming T Tsuang, Hai-Gwo Hwu.   

Abstract

BACKGROUND: In a previous linkage study of schizophrenia that included Taiwanese samples, the marker D22S278 (22q12.3) was significantly linked to schizophrenia (p = .001).
METHODS: We conducted fine mapping of the implicated genomic region, with 47 validated single nucleotide polymorphism (SNP) markers around 1 Mb of D22S278, in a Taiwanese sample of 218 pedigrees with at least 2 siblings affected with schizophrenia. We examined the association of these SNPs and their haplotypes with schizophrenia and with subgroups defined by the presence and absence of deficits in sustained attention as assessed by undegraded and degraded continuous performance tests (CPTs). We also examined subgroups defined by deficits in categories achieved in the Wisconsin Card Sort Test (WCST).
RESULTS: Three of five candidate vulnerability genes (RASD2, APOL5, MYH9, EIF3S7, and CACNG2), which had marginally significant associations with schizophrenia, had significant associations with schizophrenic patients who did not have deficits in sustained attention on the undegraded CPT (RASD2 gene SNP rs736212; p = .0008 with single locus analysis) and the degraded CPT (MYH9 gene haplotype 1-1-1-1 of SNP rs3752463 - rs1557540 - rs713839 - rs739097; p = .0059 with haplotype analysis). We also found a significant association for patients who showed no deficits in executive function as measured by categories achieved in the WCST (CACNG2 gene haplotype 2-1-1-1 of SNP rs2267360 - rs140526 - rs1883987 - rs916269; p = .0163 with haplotype analysis).
CONCLUSIONS: The genes RASD2, MYH9, and CACNG2 might be vulnerability genes for neuropsychologically defined subgroups of schizophrenic patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18571626     DOI: 10.1016/j.biopsych.2008.04.035

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  28 in total

Review 1.  Synapsin III: role in neuronal plasticity and disease.

Authors:  Barbara Porton; William C Wetsel; Hung-Teh Kao
Journal:  Semin Cell Dev Biol       Date:  2011-07-30       Impact factor: 7.727

2.  De novo single-nucleotide and copy number variation in discordant monozygotic twins reveals disease-related genes.

Authors:  Nirmal Vadgama; Alan Pittman; Michael Simpson; Niranjanan Nirmalananthan; Robin Murray; Takeo Yoshikawa; Peter De Rijk; Elliott Rees; George Kirov; Deborah Hughes; Tomas Fitzgerald; Mark Kristiansen; Kerra Pearce; Eliza Cerveira; Qihui Zhu; Chengsheng Zhang; Charles Lee; John Hardy; Jamal Nasir
Journal:  Eur J Hum Genet       Date:  2019-03-18       Impact factor: 4.246

3.  Erbin interacts with TARP γ-2 for surface expression of AMPA receptors in cortical interneurons.

Authors:  Yanmei Tao; Yong-Jun Chen; Chengyong Shen; Zhengyi Luo; C Ryan Bates; Daehoon Lee; Sylvie Marchetto; Tian-Ming Gao; Jean-Paul Borg; Wen-Cheng Xiong; Lin Mei
Journal:  Nat Neurosci       Date:  2013-01-27       Impact factor: 24.884

Review 4.  Myosin motors at neuronal synapses: drivers of membrane transport and actin dynamics.

Authors:  Matthias Kneussel; Wolfgang Wagner
Journal:  Nat Rev Neurosci       Date:  2013-03-13       Impact factor: 34.870

5.  Rhes, a physiologic regulator of sumoylation, enhances cross-sumoylation between the basic sumoylation enzymes E1 and Ubc9.

Authors:  Srinivasa Subramaniam; Robert G Mealer; Katherine M Sixt; Roxanne K Barrow; Alessandro Usiello; Solomon H Snyder
Journal:  J Biol Chem       Date:  2010-04-27       Impact factor: 5.157

6.  Longitudinal alterations of executive function in non-psychotic adolescents at familial risk for schizophrenia.

Authors:  Tejas S Bhojraj; Vaibhav A Diwadkar; John A Sweeney; Konasale M Prasad; Shaun M Eack; Debra M Montrose; Matcheri S Keshavan
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2010-01-29       Impact factor: 5.067

Review 7.  Psychiatric behaviors associated with cytoskeletal defects in radial neuronal migration.

Authors:  Toshifumi Fukuda; Shigeru Yanagi
Journal:  Cell Mol Life Sci       Date:  2017-05-17       Impact factor: 9.261

8.  Evidence for association of bipolar disorder to haplotypes in the 22q12.3 region near the genes stargazin, IFT27 and parvalbumin.

Authors:  Stephanie Nissen; Sherri Liang; Tatyana Shehktman; John R Kelsoe; Tiffany A Greenwood; Caroline M Nievergelt; Rebecca McKinney; Paul D Shilling; Erin N Smith; Nicholas J Schork; Cinnamon S Bloss; John I Nurnberger; Howard J Edenberg; Tatiana Foroud; Daniel L Koller; Elliot S Gershon; Chunyu Liu; Judith A Badner; William A Scheftner; William B Lawson; Evaristus A Nwulia; Maria Hipolito; William Coryell; John Rice; William Byerley; Francis J McMahon; Wade H Berrettini; James B Potash; Peter P Zandi; Pamela B Mahon; Melvin G McInnis; Sebastian Zöllner; Peng Zhang; David W Craig; Szabolics Szelinger; Thomas B Barrett; Thomas G Schulze
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2012-10-04       Impact factor: 3.568

9.  Effects of the Ras homolog Rhes on Akt/protein kinase B and glycogen synthase kinase 3 phosphorylation in striatum.

Authors:  L M Harrison; S H Muller; D Spano
Journal:  Neuroscience       Date:  2013-02-01       Impact factor: 3.590

10.  Rasd2 Modulates Prefronto-Striatal Phenotypes in Humans and 'Schizophrenia-Like Behaviors' in Mice.

Authors:  Daniela Vitucci; Annabella Di Giorgio; Francesco Napolitano; Barbara Pelosi; Giuseppe Blasi; Francesco Errico; Maria Teresa Attrotto; Barbara Gelao; Leonardo Fazio; Paolo Taurisano; Anna Di Maio; Valentina Marsili; Massimo Pasqualetti; Alessandro Bertolino; Alessandro Usiello
Journal:  Neuropsychopharmacology       Date:  2015-07-31       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.